ALCEDIAG

Back
Company description
ALCEDIAG creates and industrializes highly innovative approaches for medical diagnostics and predictive toxicology. The company benefits from over 10 years of expertise in the field of epigenetics and biomarkers applied to medical practice.

ALCEDIAG offers molecular diagnostic tools for stratification, treatment monitoring and disease progression of patients suffering from complexes pathologies. ALCEDIAG has developed a unique proprietary platform that includes a defined and precise technological workflow. The company has identified biomarkers and conceived algorithms fulfilling unmet pre-clinical and clinical needs in the field of psychiatry.
Product / Services
EDITOX® is the first test based on RNA modifications that allows fast and robust screening to assess adverse psychiatric side effects of pharmaceutical compounds.
EDITDIAG® identifies from a blood sample a unique molecular signature of each patient based on specific RNA modifications. The signature is used to characterize the status of the pathology and to monitor disease progression along with the impact of the treatment thereby reducing side-effects.
Weissmann D, et al, Translational Psychiatry, 2016 Cavarec et al, Neurotox Res, 2013
Areas of activity
Medical diagnostic / companion diagnostic
Skills
Genomics
Molecular profiling
Pharmacogenetics /pharmacogenomics
Transcriptomics
Pathologies
Psychiatry
Technologies
Molecular biology, structural and cellular (in vitro)
Address:
1684 rue de la Valsiere Cap Delta
34184 Montpellier
Country: France
Cluster:
Eurobiomed
Contact Contact member